Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation

Journal of Heart and Lung Transplantation

Volumn 30, Issue 2, 2011, Pages 175-181

  Ahya, Vivek N ^a   McShane, Pamela J ^b   Baz, Maher A ^c   Valentine, Vincent G ^d   Arcasoy, Selim M ^e   Love, Robert B ^f   Seethamraju, Harish ^g   Garrity, Edward ^b   Alex, Charles G ^h   Bag, Remzi ⁱ   Deoliveira, Nilto C ^j   Vigneswaran, Wickii T ^b   Charbeneau, Jeff ^k   Krishnan, Jerry A ^b   Durazo Arvizu, Ramon ^l   Norwick, Lourdes ^b   Bhorade, Sangeeta ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h Department of Medicine   (United States)

ⁱ INTEGRIS Nazih Zuhdi Transplant Institute   (United States)

^j UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^k UNIVERSITY OF CHICAGO   (United States)

^l LOYOLA UNIVERSITY CHICAGO   (United States)

more..

Author keywords

drug toxicity; immunosuppression; lung transplantation; mTOR (mammalian target of rapamycin) inhibitors; sirolimus; venous thromboembolism

Indexed keywords

AZATHIOPRINE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG EMBOLISM; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

AZATHIOPRINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TACROLIMUS; VENOUS THROMBOEMBOLISM;

EID: 78650961986     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2010.08.010     Document Type: Article

References (34)

1. J.D. Christie, L.B. Edwards, and P. Aurora Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report2008 J Heart Lung Transplant 27 2008 957 969
2. P. Baldo, S. Cecco, and E. Giacomin mTOR pathway and mTOR inhibitors as agents for cancer therapy Curr Cancer Drug Targets 8 2008 647 665
3. V. Napolioni, R. Moavero, and P. Curatolo Recent advances in neurobiology of tuberous sclerosis complex Brain Dev 31 2009 104 113
4. R. Sugimoto, A. Nakao, and M. Yamane Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation J Heart Lung Transplant 27 2008 921 924
5. L. Buschhausen, M. Kamm, and W. Arns Successful treatment of a severe case of idiopathic pulmonary fibrosis with rapamycin [in German] Med Klin (Munich) 100 2005 161 164
6. F. Barrueto, C. Lee, and M. Pajoumand Use of sirolimus in a case of severe paraquat poisoning Clin Toxicol (Phila) 46 2008 778 779
7. J.E. Dancey, R. Curiel, and J. Purvis Evaluating temsirolimus activity in multiple tumors: a review of clinical trials Semin Oncol 36 suppl 3 2009 S46 S58
8. C.G. Groth, L. Backman, and J.M. Morales Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine Transplantation 67 1999 1036 1042
9. J. Groetzner, F. Kur, and F. Spelsberg Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression J Heart Lung Transplant 23 2004 632 638
10. M.B. King-Biggs, J.M. Dunitz, and S.J. Park Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation Transplantation 75 2003 1437 1443
11. P.T. Pham, P.C. Pham, and G.M. Danovitch Sirolimus-associated pulmonary toxicity Transplantation 77 2004 1215 1220
12. P.N. Chhajed, M. Dickenmann, and L. Bubendorf Patterns of pulmonary complications associated with sirolimus Respiration 73 2006 367 374
13. R. Lingaraju, N. Blumenthal, and J. Mendez Venous thromboembolic disease after lung transplantation: special focus on sirolimus The Open Transplantation Journal 4 2010 1 4
14. E.S. Kahan, G. Petersen, and J.P. Gaughan High incidence of venous thromboembolic events in lung transplant recipients J Heart Lung Transplant 26 2007 339 344
15. G. Izbicki, O. Bairey, and D. Shitrit Increased thromboembolic events after lung transplantation Chest 129 2006 412 416
16. H.A. Yegen, D.J. Lederer, and R.G. Barr Risk factors for venous thromboembolism after lung transplantation Chest 132 2007 547 553
17. P. McShane, S. Bhorade, and M. Baz Sirolimus is associated with an increased risk of venous thromboembolism in lung transplantation J Heart Lung Transplant 28:2 suppl 2009 S139
18. S. Bhorade, V. Ahya, and R. Kotloff Long-term follow-up in the AIRSAC trial, a multicenter randomized clinical trial in lung transplant recipients J Heart Lung Transplant 28 suppl 2009 S119
19. J.M. Cruzado Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors Transplant Rev (Orlando) 22 2008 73 81
20. S.N. Sehgal Sirolimus: its discovery, biological properties, and mechanism of action Transplant Proc 35 suppl 2003 7S 14S
21. S.N. Sehgal Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression Clin Biochem 31 1998 335 340
22. A. Eisenreich, O. Celebi, and P. Goldin-Lang Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and paclitaxel Int Immunopharmacol 8 2008 307 311
23. T.F. Luscher, J. Steffel, and F.R. Eberli Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications Circulation 115 2007 1051 1058
24. J. Steffel, R.A. Latini, and A. Akhmedov Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design Circulation 112 2005 2002 2011
25. J.A. Muldowney III, J.R. Stringham, and S.E. Levy Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents Arterioscler Thromb Vasc Biol 27 2007 400 406
26. A. Babinska, M.S. Markell, and M.O. Salifu Enhancement of human platelet aggregation and secretion induced by rapamycin Nephrol Dial Transplant 13 1998 3153 3159
27. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm154514.htm
28. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
29. M. Pfisterer, H.P. Brunner-La Rocca, and P.T. Buser Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591
30. J.C. Dunkelberg, J.F. Trotter, and M. Wachs Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications Liver Transplant 9 2003 463 468
31. M. Montalbano, G.W. Neff, and N. Yamashiki A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications Transplantation 78 2004 264 268
32. C. Toso, G.A. Meeberg, and D.L. Bigam De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects Transplantation 83 2007 1162 1168
33. R.M. Langer, and B.D. Kahan Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients Transplantation 76 2003 318 323
34. K. McNeil, A.R. Glanville, and T. Wahlers Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients Transplantation 81 2006 998 1003